Added to YB: 2026-01-27
Pitch date: 2026-01-24
AQST [neutral]
Aquestive Therapeutics, Inc.
+22.22%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Market Cap
$445.3M
Pitch Price
$3.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.70
P/E
-5.25
EV/Sales
8.24
Sector
Pharmaceuticals
Category
special_situation
Four Biotechs I’m Watching After the JPM Healthcare Conference - Aquestive Therapeutics, Inc.
AQST (watchlist): Needle-free sublingual epinephrine film for anaphylaxis using PharmFilm® tech. PDUFA Jan 31 2026. Would be first FDA-approved non-injectable epinephrine, addressing needle anxiety/misuse of auto-injectors. Peak levels 10-15min, comparable exposure to current options. Binary event for $424M mcap co. Key risks: FDA scrutiny on real-world absorption consistency, potential labeling limits.
Read full article (2 min)